Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

A significant negative impact on HRQoL of IFN treatment was demonstrated, however the impact were reversible when treatment was stopped.